HK1202241A1 - 自身免疫抗體 - Google Patents

自身免疫抗體

Info

Publication number
HK1202241A1
HK1202241A1 HK15102727.9A HK15102727A HK1202241A1 HK 1202241 A1 HK1202241 A1 HK 1202241A1 HK 15102727 A HK15102727 A HK 15102727A HK 1202241 A1 HK1202241 A1 HK 1202241A1
Authority
HK
Hong Kong
Prior art keywords
autoimmune antibodies
autoimmune
antibodies
Prior art date
Application number
HK15102727.9A
Other languages
English (en)
Inventor
Peter Berndt
Barbara Klughammer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1202241A1 publication Critical patent/HK1202241A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15102727.9A 2012-06-07 2015-03-17 自身免疫抗體 HK1202241A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12171126 2012-06-07
PCT/EP2013/061430 WO2013182537A1 (en) 2012-06-07 2013-06-04 Autoimmune antibodies

Publications (1)

Publication Number Publication Date
HK1202241A1 true HK1202241A1 (zh) 2015-09-25

Family

ID=48570148

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102727.9A HK1202241A1 (zh) 2012-06-07 2015-03-17 自身免疫抗體

Country Status (11)

Country Link
US (1) US20130331287A1 (zh)
EP (1) EP2858669A1 (zh)
JP (1) JP2015527564A (zh)
KR (1) KR20150017344A (zh)
CN (1) CN104334190A (zh)
BR (1) BR112014028659A2 (zh)
CA (1) CA2870015A1 (zh)
HK (1) HK1202241A1 (zh)
MX (1) MX2014014829A (zh)
RU (1) RU2014154144A (zh)
WO (1) WO2013182537A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3102944B1 (en) 2014-02-04 2018-10-10 CellTrend GmbH Diagnosis of cancer by detecting auto-antibodies against egf-receptor
CN114790235B (zh) * 2021-01-26 2024-10-18 深圳睿科灏康医学科技有限公司 针对egfr外显子19缺失突变的新生抗原及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101531400B1 (ko) * 2003-06-27 2015-06-26 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
ES2385613T3 (es) * 2006-09-18 2012-07-27 Boehringer Ingelheim International Gmbh Método para tratar cánceres que portan mutaciones de EGFR
WO2010073905A1 (ja) * 2008-12-25 2010-07-01 シャープ株式会社 動画像視聴装置
WO2011073905A1 (en) 2009-12-14 2011-06-23 Koninklijke Philips Electronics N.V. Novel tumor markers
US8828391B2 (en) * 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer

Also Published As

Publication number Publication date
CA2870015A1 (en) 2013-12-12
JP2015527564A (ja) 2015-09-17
EP2858669A1 (en) 2015-04-15
MX2014014829A (es) 2015-02-12
CN104334190A (zh) 2015-02-04
BR112014028659A2 (pt) 2017-07-25
KR20150017344A (ko) 2015-02-16
RU2014154144A (ru) 2016-07-27
WO2013182537A1 (en) 2013-12-12
US20130331287A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
HUS2400016I1 (hu) FCRN elleni antitestek
IL264558A (en) Anti–il–23p19 antibodies
HK1204571A1 (zh) 蛋白酶調節的抗體
HK1210192A1 (zh) 抗體
EP2930240A4 (en) ANTI-FOLR1 ANTIBODY
EP2844290A4 (en) NOVEL ANTIBODIES
ZA201407316B (en) Anti-fgfr2 antibody
EP2832855A4 (en) NEW ANTI-SIGLEC ANTIBODY-15
EP2826790A4 (en) GREMLIN-1 ANTIBODY
ZA201407079B (en) Cdr-modified anti-siglec-15 antibody
HK1210186A1 (zh) 抗體
PL2935330T3 (pl) Przeciwciała przeciw notch3
GB201220242D0 (en) Antibody
EP2804876A4 (en) NEW ANTIBODIES
EP2848633A4 (en) ANTI-CXADR ANTIBODY
HK1202241A1 (zh) 自身免疫抗體
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß
IL235188A0 (en) Antibodies against c-pdgf
GB201209584D0 (en) Modified antibodies
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations